Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults
Condition(s) studied
Investigational drug(s) / intervention(s)
Recombinant Poliomyelitis Vaccine (rPV): Recombinant Poliomyelitis Vaccine (VLP) is manufactured by Serum Institute of India Pvt. Ltd.
Inactivated Poliomyelitis Vaccine (IPOL): IPOL (inactivated poliovirus vaccine) is a marketed Sanofi
Study summary
The primary purpose of this study is to test a new experimental recombinant Poliomyelitis vaccine (rPV) in comparison to the commercially available inactivated poliovirus vaccine. The design of the study is double-blinded, randomised and active controlled. The active controlled product is considered the commercially available vaccine (IPOL).
Eligibility
Primary outcome measure(s)
- The incidence, severity and relationship of solicited adverse events (AEs) during 7-day and unsolicited AEs during 30-day follow-up period after rPV and IPOL vaccination — 30 days
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Doherty Clinical Trials Limited | East Melbourne | Victoria | Recruiting |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07688369 on ClinicalTrials.gov ↗ ← All trials in Australia